Moura-Neto José A, Misael Ana Maria, Silva Dirceu Reis da, D'Avila Ronaldo, Andreoli Maria Claudia Cruz, Kraychete Angiolina, Bastos Kleyton, Nascimento Marcelo Mazza do
Sociedade Brasileira de Nefrologia, São Paulo, Brazil.
Grupo CSB, Salvador, Bahia, Brazil.
J Bras Nefrol. 2020 Aug 26;42(2 suppl 1):49-50. doi: 10.1590/2175-8239-JBN-2020-S113.
Chloroquine and hydroxychloroquine have shown promising preliminary results and have been discussed as therapeutic options for patients with Covid-19. Despite the lack of robust evidence demonstrating the benefits and justifying the use of one of these drugs, the final decision is the responsibility of the attending physician and should be individualized and shared, whenever possible. This position statement recommends dosage adjustment for these drugs in the context of renal impairment.
氯喹和羟氯喹已显示出有前景的初步结果，并已被作为2019冠状病毒病患者的治疗选择进行讨论。尽管缺乏有力证据证明这些药物之一的益处并证明其使用合理，但最终决定权在主治医生，且应尽可能个体化并共享。本立场声明建议在肾功能损害的情况下对这些药物进行剂量调整。
